ClinicalTrials.govpublic full text
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
pancreatic cancer, first-line, metastatic pancreatic cancer, immunotherapy, angiogenesis inhibitors, anlotinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 905259
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.